Table 3a.
Data for all patients with Kadish stage C esthesioneuroblastoma in this series
Patient no. | Age/sex | Hyam’s grade | Resection extent | Radiation (cGy) | Chemotherapy | Recurrence (months) | Death (months) | Follow-up (months) |
---|---|---|---|---|---|---|---|---|
1 | 69/M | High | GTR | No | No | No | 22.5 | 22.5 |
2 | 70/M | High | GTR | No | No | 13.2 | 27.0 | 27.0 |
3 | 46/M | High | GTR | XRT, 6000 | Yes | No | No | 9.8 |
4 | 52/M | High | GTR | No | No | No | No | 31.5 |
5 | 63/M | High | GTR | IMRT, 6600 | No | No | No | 64.9 |
6 | 40/M | High | GTR | No | No | 41.4 | 83.0 | 83.0 |
7 | 50M | High | STR | IMRT, 6600 | Yes | No | No | 12.3 |
8 | 36/M | High | GTR | No | No | No | No | 27.7 |
9 | 42/F | High | STR | XRT | Cisplatin, etoposide | 23.3 | 40.0 | 40.0 |
10 | 31/M | High | STR | XRT, 7000 | Cytoxan Vincristine | No | No | 175.4 |
11 | 40/M | Low | GTR | IMRT, 6572 | Carboplatin | No | No | 43.7 |
12 | 51/F | Low | GTR | XRT | No | No | No | 1.3 |
13 | 62/M | Low | GTR | IMRT | No | No | No | 68.2 |
14 | 66/F | Low | GTR | No | No | 48.3 | No | 52.5 |
15 | 39/M | Low | GTR | No | No | 12.1 | No | 147.3 |
16 | 52M | Low | GTR | No | No | No | No | 72.5 |
17 | 44/M | Low | GTR | IMRT, 6000 | No | No | No | 63.1 |
18 | 63/M | Low | GTR | IMRT, 6600 | Cisplatin | No | 15.9 | 15.9 |
19 | 64/M | NA | GTR | No | No | No | No | 1.4 |
20 | 49/M | NA | STR | XRT | No | 75.1 | No | 85.1 |
GTR = gross total resection, IMRT = intensity-modulated radiotherapy, STR = subtotal resection, XRT = external beam radiotherapy,.